What did Carlyle pay for Vantive Kidney Care (Baxter)?

Carlyle acquired Vantive Kidney Care (Baxter) for $3.80B in 2024, equivalent to 0.80x revenue. Target revenue was approximately $4513.0M.

What does Vantive Kidney Care (Baxter) do?

Vantive Kidney Care (Baxter) is a medical devices business.

What multiple did Carlyle pay for Vantive Kidney Care (Baxter)?

0.80x revenue, based on disclosed deal value of $3.80B and disclosed financials.

M&A TRANSACTION · 2024

Vantive Kidney Care (Baxter) acquired by Carlyle

$3.80B· 0.80x revenue

Target

Vantive Kidney Care (Baxter)

Acquirer

Carlyle

Private Equity buyer

Disclosed financials at time of acquisition

Revenue

$4513.0M

EBITDA

—

Deal Value

$3.80B

EV/EBITDA

—

Context

This $3.80B acquisition of Vantive Kidney Care (Baxter) by Carlyle sits in the medical devices sub-vertical. Carlyle is acquiring as a private equity buyer; see how PE acquirers typically price medical devices businesses on our Medical Devices PE buyer-pool page.

Source

Data sourced from SEC filings and press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Vantive Kidney Care (Baxter) acquisition.

Citation: ExitValue.ai. (2024). Vantive Kidney Care (Baxter) acquired by Carlyle. https://exitvalue.ai/deals/vantive-kidney-care-baxter-acquired-by-carlyle-hc-2024-0025